Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves? Orbitopathy

Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves? Orbitopathy Vol. 90, No. 9 5234-5240 ปี 2548   Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy George J. Kahaly, Susanne Pitz, Gerhard Hommel and Manuela Dittmar Departments of Medicine I (G.J.K., M.D.), Biology (M.D.), Ophthalmology (S.P.), and Medical Statistics (G.H.), Gutenberg University, Mainz 55101, Germany Address all correspondence and requests for reprints to: Dr. George J. Kahaly, University Hospital, Mainz 55101, Germany, E-mail: gkahaly@mail.uni-mainz.de . Context: Glucocorticoids are effective for severe Graves’ orbitopathy (GO), which causes substantial morbidity. The question at issue is how best to use them. Objective: The objective of this study was to optimize glucocorticoid application in GO. Design: The study design was a randomized trial over 12 wk with 6-month follow-up. Setting: The study was performed at university joint thyroid and ophthalmic clinics. Patients: Seventy euthyroid out-patients with untreated, active, and severe GO were studied. […]

Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome

  Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome JCEM ปี 2547 Author: Stefano Palomba, Francesco Orio, Jr., Angela Falbo, Francesco Manguso, Tiziana Russo, Teresa Cascella, Achille Tolino, Enrico Carmina, Annamaria Colao and Fulvio Zullo Department of Obstetrics and Gynecology (S.P., A.F., T.R., F.Z.), University “Magna Graecia” of Catanzaro, 80131 Naples, Italy; Departments of Molecular and Clinical Endocrinology and Oncology (F.O., T.C., A.C.), Internal Medicine (F.M.), and Obstetrics and Gynecology (A.T.), University “Federico II” of Naples, 80138 Naples, Italy; and Department of Endocrinology (E.C.), University of Palermo, 90128 Palermo, Italy Context: Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients. Objective: The goal of this study was to compare the effectiveness […]

Diabetes Care :: May 2007, Volume 30, Number 5

  Diabetes Care :: May 2007, Volume 30, Number 5 May 2007, Volume 30, Number 5 ปี 2548 Contents: May 2007, Volume 30, Number 5   [Index by Author]  [Cover Caption]  Original Articles       Clinical Care/Education/Nutrition       Epidemiology/Health Services/Psychosocial Research       Emerging Treatments and Technologies       Pathophysiology/Complications       Cardiovascular and Metabolic Risk    Brief Reports       Clinical Care/Education/Nutrition       Epidemiology/Health Services/Psychosocial Research       Pathophysiology/Complications       Cardiovascular and Metabolic Risk    Reviews/Commentaries/ADA Statements       Review Articles       Perspectives on the News

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes Diabetes Care 28:2261-2266, 2005 ปี 2548   Reviews/Commentaries/ADA Statements Meta-Analysis. ABSTRACT OBJECTIVE—Angiotensin II has been shown to increase hepatic glucose production and decrease insulin sensitivity. Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes.  RESEARCH DESIGN AND METHODS—Three reviewers conducted a systematic literature search of Medline, EMBASE, CINAHL, and the Cochrane Library (1966 to present) to extract a consensus of trial data involving an ACEI or ARB with an end point of new-onset type 2 diabetes. Studies were included if they were randomized controlled trials verses placebo/routine therapy. A random-effects model was utilized. Subgroup and sensitivity analyses were conducted.  RESULTS—Eleven trials were identified, including 66,608 patients. An ACEI or ARB prevented new-onset type 2 diabetes (odds ratio 0.78 [95% CI 0.73–0.83]). The influence of either an ACEI (six trials) or […]

Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy

Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy Diabetes Care 28:2106-2112, 2005 ปี 2548   Authors: Kasper Rossing, MD1, Katrine J. Schjoedt, MD1, Ulla M. Smidt1, Frans Boomsma, PHD2 and Hans-Henrik Parving, MD, DMSC1,3 OBJECTIVES: –  The objective of this study was to evaluate the safety and short-term effect of adding spironolactone to conventional antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor or an angiotensin II receptor blocker (ARB) on albuminuria and blood pressure in type 2 diabeticpatients with nephropathy. RESEARCH DESIGN AND METHODS—Twenty-one type 2 diabetic patients with nephropathy were enrolled in a randomized, double-masked, cross-over study. Patients were treated in random order with spironolactone 25 mg once daily and matched placebo for 8 weeks, respectively, in addition to ongoing antihypertensive treatment including diuretics and maximally recommended doses of an ACE inhibitor and/or an ARB. At the end of each treatment […]